GKT137831: Selective Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a dual NADPH oxidase inhibitor with Ki values of 140 nM for Nox1 and 110 nM for Nox4, providing selective blockade of reactive oxygen species (ROS) generation (APExBIO). It attenuates downstream signaling pathways including Akt/mTOR and NF-κB, which are implicated in inflammation and fibrosis (Yang et al. 2025). In vivo, oral GKT137831 (30–60 mg/kg/day) reduces pulmonary vascular remodeling, right ventricular hypertrophy, and liver fibrosis in mouse models. Solubility is ≥39.5 mg/mL in DMSO, with recommended storage at -20°C. Clinical studies support its translational value in oxidative stress-related diseases.

Biological Rationale

Reactive oxygen species (ROS) are chemically reactive molecules derived from oxygen. Excessive ROS contribute to pathological remodeling, chronic inflammation, and fibrosis in various tissues (Yang et al. 2025). NADPH oxidase isoforms Nox1 and Nox4 are primary enzymatic sources of ROS in vascular and fibrotic diseases. Selective inhibition of Nox1/Nox4 enables precise modulation of disease-associated redox signaling while minimizing off-target effects. GKT137831 was developed to address the need for potent, isoform-selective NADPH oxidase inhibition in translational models (APExBIO).

Mechanism of Action of GKT137831

GKT137831 is a small molecule that competitively inhibits NADPH oxidase isoforms Nox1 and Nox4 with Ki values of 140 nM and 110 nM, respectively (APExBIO). This inhibition reduces ROS production at the source, attenuating the activation of redox-sensitive signaling pathways such as:

• Akt/mTOR pathway: Downregulated in models treated with GKT137831, leading to decreased cellular proliferation (as detailed in related review).
• NF-κB pathway: Suppressed following Nox1/Nox4 inhibition, reducing pro-inflammatory gene expression.
• TGF-β1 expression: Lowered, resulting in reduced fibrotic signaling.
• PPARγ modulation: Expression changes support anti-inflammatory and anti-fibrotic phenotypes.

GKT137831 also lowers hypoxia-induced hydrogen peroxide (H₂O₂) release in human pulmonary artery endothelial and smooth muscle cells. This direct reduction of ROS prevents downstream membrane lipid peroxidation, a process central to ferroptosis and tissue damage (Yang et al. 2025).

Evidence & Benchmarks

• GKT137831 inhibits Nox1/Nox4 with Ki values of 140 nM (Nox1) and 110 nM (Nox4) in biochemical assays (APExBIO).
• In vitro treatment reduces H₂O₂ release in hypoxia-challenged human pulmonary artery endothelial cells (HPAECs) and smooth muscle cells (HPASMCs) (Yang et al. 2025).
• Oral GKT137831 (30–60 mg/kg/day) attenuates pulmonary vascular remodeling and right ventricular hypertrophy in chronic hypoxia mouse models (Yang et al. 2025).
• Reduces liver fibrosis and diabetes-accelerated atherosclerosis in vivo (APExBIO).
• Clinical studies indicate safety and efficacy in oxidative stress-related disorders (see product dossier).

This article updates recent reviews (see comparison), by providing consolidated quantitative benchmarks and highlighting direct modulation of membrane oxidation as clarified by Yang et al. (2025).

Applications, Limits & Misconceptions

GKT137831 is primarily used in preclinical and translational models of oxidative stress, vascular remodeling, fibrosis, and diabetes-accelerated atherosclerosis. Its specificity enables research into:

• Mechanistic dissection of ROS-driven disease pathways.
• Therapeutic modulation of Akt/mTOR and NF-κB signaling.
• Investigation of ROS and lipid peroxidation in ferroptosis, complementing findings on membrane repair mechanisms (Yang et al. 2025).

For a foundational overview, this article details GKT137831’s selectivity and translational context; the present review further delineates its solubility, workflow parameters, and emerging links to membrane integrity.

Common Pitfalls or Misconceptions

• Non-selective inhibition: GKT137831 does not broadly inhibit all NADPH oxidase isoforms; Nox2 and other family members are minimally affected at relevant concentrations.
• Solubility constraints: The compound is insoluble in water and must be solubilized in DMSO (≥39.5 mg/mL) or, with warming/sonication, in ethanol (≥2.96 mg/mL).
• Storage stability: Long-term storage of solutions is not recommended; prepare fresh aliquots as needed.
• Clinical translation: While clinical trials are ongoing, most mechanistic data derive from preclinical models; results may not extrapolate directly to all human disease settings.
• ROS-independent pathways: GKT137831 will not affect redox-independent disease mechanisms.

Workflow Integration & Parameters

For in vitro studies, GKT137831 is typically used at final concentrations of 0.1–20 μM, with incubation periods around 24 hours. The compound is highly soluble in DMSO, allowing preparation of concentrated stock solutions (≥39.5 mg/mL). Ethanol can be used for moderate solubility (≥2.96 mg/mL with warming and sonication), but water should be avoided due to insolubility. For in vivo experiments, oral dosing in mice ranges from 30 to 60 mg/kg/day. Storage at -20°C is recommended for powder; solutions should not be stored long-term (APExBIO).

For advanced applications and workflow strategies, this in-depth article extends the discussion to clinical trial design and redox signaling integration, while the present review focuses on practical, verifiable parameters and pitfalls.

Conclusion & Outlook

GKT137831, supplied by APExBIO, is a validated, potent, and selective dual Nox1/Nox4 inhibitor for oxidative stress research. Its nanomolar inhibitory constants, robust in vivo efficacy, and predictable solubility/stability profile make it a cornerstone tool for dissecting ROS-driven pathology and for bridging basic redox biology with translational medicine. Ongoing clinical studies and mechanistic advances in membrane-level redox regulation (including recent insights into ferroptosis) highlight the expanding landscape for GKT137831 in research and therapeutic development (Yang et al. 2025).